Callisto
About
Pipeline
Clinical Trials
Investor Relations
News
Blog
Nothing Found
It seems we can’t find what you’re looking for. Perhaps searching can help.
Search
About
Board of Directors
Business Development
Corporate Governance
Management Team
Albert J. Henry, M.B.A.
ANNUAL MEETING OF STOCKHOLDERS
Archived News
Bernard F. Denoyer, CPA
Biodefence Program introduction
Biological studies on Multiple Myeloma
Callisto R&D Facility
Callisto Stock Information
Careers
Christoph Bruening
Clinical studies
Clinical summary
Clinical Trials
Atiprimod Trials
L-Annamycin Trials
SP-304 Trials
Collaborators
Contact
Diagnostic Test for OCD
Disclaimer
Donald H. Picker, Ph.D.
DRUG PIPELINE GOALS
Edwin Snape, Ph. D.
Gabriele M. Cerrone, M.B.A.
Gary S. Jacob, Ph.D.
GCRA for Colon Cancer
GCRA Publications
GCRA Publications
GUANLIB
Iain Ross
INFORMATION FOR PATIENTS
Investor Relations
Kunwar Shailubhai, Ph.D. & M.B.A.
Legal
Michael Zelefsky, M.D.
News
News
Open Positions
Personnel and staff
Pipeline
Atiprimod
Atiprimod Science
L-Annamycin
L-Annamycin Science
Pre-Clinical Programs
Degrasyns
SP-304
SP-304 Markets
SP-304 Science
PROFILE
SEC Filings
SHAREHOLDER FAQ
Sitemap
Technology Page
Third Party Entry
Welcome to callisto pharmaceuticals